Therapeutic Solutions
International Announces Clinical Proof of Concept of Nanoparticle
Pterostilbene Formulation: NanoStilbene™
Early Clinical Trial Data Supports
Enhanced Biodistribution of
NanoStilbene™ Compared to Standard Pterostilbene When Orally
Administered
Oceanside, CA --
July
02,
2018 -- InvestorsHub NewsWire -- Therapeutics Solutions
International, Inc., (OTC Markets: TSOI)
announced today pilot clinical data providing proof of concept that
its NanoStilbene™ formulation of
pterostilbene more effectively increases blood levels of the
molecule as compared to conventional formulations. The clinical
trial involves administration of NanoStilbene or comparator
formulations of pterostilbene, to healthy volunteers, followed by a
series of blood draws to determine the concentration of the
compound.
"These early studies
are critical to establishing the efficacy of our nanoparticle
formulations to effectively deliver pterostilbene to the body,"
said Timothy Dixon, President, and CEO of Therapeutic Solutions
International. "We are dedicated to developing First Class
nutraceutical formulations that are science-driven. Through
performing scientific validation at each step of the development
process, we aim to fulfill this commitment to the
Industry."
Pterostilbene is a
naturally occurring analog of resveratrol, which has been published
in the peer-reviewed literature to suppress the growth of various
types of cancers1 including cervical
cancer2, lung
cancer3, triple negative
breast cancer4, prostate
cancer5, and
glioma6.
"I am extremely
pleased with the promising initial data we are receiving
demonstrating efficacy of the NanoStilbene formulation to deliver
enhanced concentrations of pterostilbene to the patient's blood
stream." Said Dr. James Veltmeyer, Chief Medical Officer of the
Company. "Given the ability of pterostilbene to enhance the
efficacy of chemotherapeutic drugs7, as well as having
activity as a monotherapy in animal models, we are hoping to expand
the use of this highly interesting molecule."
1 Chen et al. Apoptotic
and Nonapoptotic Activities of Pterostilbene against Cancer. Int.
J. Mol. Sci. 2018, 19(1), 287; http://www.mdpi.com/1422-0067/19/1/287
2
Chatterjee et al.
Resveratrol and Pterostilbene Exhibit Anticancer Properties
Involving the Downregulation of HPV Oncoprotein E6 in Cervical
Cancer Cells. Nutrients. 2018 Feb 21;10(2) http://www.mdpi.com/2072-6643/10/2/243
3
Ma et al.
Pterostilbene exerts anticancer activity on non-small-cell lung
cancer via activating endoplasmic reticulum
stress. Sci Rep. 2017 Aug 14;7(1):8091. https://www.nature.com/articles/s41598-017-08547-0
4
Su et al.
Pterostilbene inhibits triple-negative breast cancer metastasis via
inducing microRNA-205 expression and negatively modulates
epithelial-to-mesenchymal transition. J Nutr
Biochem.
2015 Jun;26(6):675-85 https://www.ncbi.nlm.nih.gov/pubmed/25792283
5
Li et al.
Pterostilbene acts through metastasis-associated protein 1 to
inhibit tumor growth, progression and metastasis in prostate
cancer. PLoS
One.
2013;8(3):e57542.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057542
6
Huynh et
al. Pterostilbene suppressed irradiation-resistant glioma stem
cells by modulating GRP78/miR-205 axis. J Nutr
Biochem.
2015 May;26(5):466-75. https://www.ncbi.nlm.nih.gov/pubmed/25736407
7
Schmidt
et al. Case-specific potentiation of glioblastoma drugs by
pterostilbene. Oncotarget.
2016 Nov 8;7(45):73200-73215. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341973/
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com and e-commerce at
www.youcanordernow.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION